Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD AML

The FLT3-ITD mutation is associated with a high relapse rate for patients with AML even after allogeneic hematopoietic stem cell transplantation (HSCT). Sorafenib is a tyrosine kinase inhibitor which inhibits the FLT3 tyrosine kinase and has shown encouraging activity in FLT3-ITD AML. We conducted a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Biol Blood Marrow Transplant
Autori principali: Chen, Yi-Bin, Li, Shuli, Lane, Andrew A., Connolly, Christine, Del Rio, Candice, Valles, Betsy, Curtis, Morgan, Ballen, Karen, Cutler, Corey, Dey, Bimalangshu R., El-Jawahri, Areej, Fathi, Amir T., Ho, Vincent T., Joyce, Amy, McAfee, Steven, Rudek, Michelle, Rajkhowa, Trivikram, Verselis, Sigitas, Antin, Joseph H., Spitzer, Thomas R., Levis, Mark, Soiffer, Robert
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4253683/
https://ncbi.nlm.nih.gov/pubmed/25239228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2014.09.007
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi